Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy-Reference-Cited by-同舟云学术

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Published:2015-01-01 Issue:1 Volume:125 Page:71-81
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hughes Charlotte F. M.¹²,Khot Amit¹,McCormack Christopher²³,Lade Stephen⁴,Westerman David A.¹²⁴,Twigger Robert¹,Buelens Odette¹,Newland Kate¹,Tam Constantine¹,Dickinson Michael¹,Ryan Gail⁵,Ritchie David¹²,Wood Colin¹,Prince H. Miles¹²

Affiliation:

1. Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;

2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;

3. Department of Dermatology, St. Vincent’s Hospital Department of Medicine, Melbourne, Australia;

4. Division of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; and

5. Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Abstract

Key Points Chemotherapy results in a short median time to next treatment in patients with mycosis fungoides/Sézary syndrome. α-interferon achieves a superior time to next treatment compared with chemotherapy, regardless of stage.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/1/71/1383658/71.pdf

Reference58 articles.

1. WHO-EORTC classification for cutaneous lymphomas.;Willemze;Blood,2005

2. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.;Criscione;Arch Dermatol,2007

3. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.;Weinstock;Am J Public Health,1999

4. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).;Olsen;Blood,2007

5. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.;Agar;J Clin Oncol,2010

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma;Dermatologic Therapy;2023-12-19

2. Clinical characteristics, initial treatment, and prognosis of mycosis fungoides and Sézary syndrome: A retrospective, single-center study at the Centre Hospitalier Universitaire of Quebec;Annales de Dermatologie et de Vénéréologie;2023-12

3. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom;Cancers;2023-11-30

4. Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma;Hematological Oncology;2023-11-16

5. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies;Blood Advances;2023-10-31